Product Description
Mechanisms of Action: CRFR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Stress Disorders, Post-Traumatic|Irritable Bowel Syndrome|Depressive Disorder, Major|Alcoholism
Phase 1: Phobia, Social|Healthy Volunteers|Adrenogenital Syndrome|Depressive Disorder|Adrenal Hyperplasia, Congenital|Adrenocortical Hyperfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NBI-77860-1401 | P1 |
Withdrawn |
Adrenal Hyperplasia, Congenital|Adrenogenital Syndrome|Adrenocortical Hyperfunction |
2015-10-01 |
2019-03-20 |
Treatments |
|
| 10-AA-0046 | P2 |
Completed |
Alcoholism |
2015-09-01 |
2019-03-19 |
Treatments |
|
| IRB00022717 | P2 |
Completed |
Stress Disorders, Post-Traumatic |
2014-08-01 |
2019-03-19 |
Treatments |
|
| AFTER | P2 |
Completed |
Stress Disorders, Post-Traumatic |
2014-06-30 |
2021-06-26 |
Primary Endpoints |
|
| CRI109244 | P2 |
Withdrawn |
Irritable Bowel Syndrome |
2012-11-01 |
2019-03-21 |
Treatments |
|
| NCT00733980 | P2 |
Completed |
Depressive Disorder, Major |
2010-06-18 |
2019-03-18 |
Treatments |
|
| CRS-110300 | P1 |
Completed |
Healthy Volunteers |
2008-03-01 |
2019-03-21 |
Treatments |
|
| 2006-004212-48 | P2 |
Completed |
Unknown |
2008-01-10 |
2022-03-12 |
Treatments |
|
| CRH108571 | P1 |
Completed |
Phobia, Social |
2008-01-10 |
2019-03-22 |
Treatments |
|
| CRS105511 | P1 |
Completed |
Depressive Disorder |
2007-01-08 |
2019-03-21 |
||
| 2007-000929-22 | P2 |
Terminated |
Irritable Bowel Syndrome |
None |
2022-03-12 |
Treatments |